Background and objectives Assessment of HBV-NAT testing compared to HBsAg and anti-HBc screening in German blood establishments for the period 2008-2015.
Introduction
To review the current testing strategy for hepatitis B virus (HBV) in German blood donors, the Paul-Ehrlich-Institut (PEI) evaluated the yield of positive donations for HBV nucleic acid test (NAT) and hepatitis B surface antigen (HBsAg), as well as the benefit of antibody hepatitis B core antigen (anti-HBc) screening for the period 2008-2015 [1, 2] . Since 10/2006, screening for anti-HBc has been introduced in addition to HBsAg [3] . At about the same time, most blood establishments (BE) in Germany voluntarily introduced HBV-NAT for donor screening.
Nevertheless, five cases of transfusion-related HBV infections have still been reported since then, all caused by donations in the anti-HBc-negative window period (WP) of HBV [2] . HBV-NAT has the potential to detect HBV in the WP earlier than HBsAg screening, but its benefit depends on the relative sensitivity to HBsAg tests. However, most BE in Germany perform minipool-(MP)-NAT which is associated with a reduced sensitivity depending on the pool size used. In fact, studies have reported different efficacy of MP-NAT, ranging from marginal benefit [4, 5] to superior detection compared to HBsAg tests [6] [7] [8] [9] [10] .
This study aimed to determine the yield of HBsAg-/ anti-HBc-negative NAT-only in the HBV-WP, the test performance of HBsAg as compared to HBV-NAT and the implication for the residual risk of HBV transmission from an infectious but non-reactive HBsAg or HBV-NAT donation. Furthermore, the safety margin by additional anti-HBc screening was evaluated regarding the prevention of transfusion-transmitted HBV by chronic HBV carriers including occult HBV infection (OBI).
Material and methods

HBsAg, anti-HBc and HBV-NAT tested donations 2008-2015
Data on HBV-NAT-only, HBsAg and anti-HBc were collected as described previously [1] :
(i) HBV-NAT positive, HBsAg and anti-HBc negative, that is, "NAT-only". (ii) HBsAg positive, HBV-NAT negative, in anti-HBc positive as well as negative, if anti-HBc negative referred to as "HBsAg-only". (iii) Anti-HBc and HBV-NAT positive, HBsAg negative, that is, "occult HBV infection" (OBI). (iv) Information on the HBV-NAT (limit of detection (LoD) and MP size) and HBsAg kit used, viral load and HBV genotype in NAT-only, and recent HBV vaccination.
Testing algorithm
Initially reactive (HBsAg, anti-HBc, HBV-NAT) in the first blood sample had to be repeated twice in the same test, and if repeatedly reactive (RR) further testing was required [3] :
(i) HBsAg RR/anti-HBc negative: neutralization assay in the first HBsAg test or retest in a different 2nd HBsAg test. (ii) HBsAg and anti-HBc RR was considered HBV confirmed without further testing.
(iii) Anti-HBc RR and HBsAg negative were further tested in up to two supplemental anti-HBc tests (final anti-HBc result by 2:1 principle) and/or by HBV-ID-NAT (LoD ≤ 12 IU/ml). (iv) HBV DNA RR was considered HBV confirmed regardless of further tests.
HBV-NAT and HBsAg test kits
Tests involved in the NAT-only cases 2008-2015 ( (Table S1 ).
Comparison of the sensitivity of MP-NAT vs. HBsAg (HBV seroconversion study)
The three HBsAg test kits involved in the NAT-only cases were tested on 30 commercial HBV seroconversion panels (377 serial samples) as described in Table S2 . HBV DNA was quantified with cobas HBV for use with the cobas 6800 System (Roche Diagnostics GmbH, Mannheim, Germany; sample volume 200 µl (in plasma, LoD 15.5 IU/ml, lower limit of quantification 25 IU/ml). HBV DNA IU/ml was converted into copies/ml by factor 5.82, according to the package insert. Timing of HBsAg detection and corresponding viral load was determined by regression analysis: time(t)=ln (y/a)/b (y = HBsAg cut-off, a = slope, b = axial section); HBV DNA at HBsAg cut-off y = b 9 exp(a 9 t). The x/y data pairs were from the first positive to the last continuously growing curve point of HBV detection. HBV doubling time was calculated by t 2 = ln(2)/a. The effective LoD per ID was used to determine timing of MP-NAT detection: time(t) =ln(y/a)/b (y = LoD). Comparison of HBV detection between HBsAg test and HBV-NAT was the difference in the detection performance in the first positive serial panel member for each test and panel and aggregated for all 30 panels as median, minimum, maximum and interquartile range.
Results of the three HBsAg kits were shown as weighted average according to their use frequency in the NAT-only cases: Prism 50Á0%, Enzygnost 35Á7% and Architect 14Á3%. The ratio of subviral HBsAg particles to HBV virions was determined according to [11] : One ng HBsAg derived from the PEI HBsAg standard [12] corresponds to 2Á2 9 10 8 subviral particles (~5 9 10 7 HBV virions), multiplied by the analytical sensitivity for HBsAg detection (9Á4 pg/ml on average), divided by the HBV DNA copies/ ml at positive HBsAg cut-off (1 HBV DNA copy/ml = 1 HBV virion/ml).
Residual risk of HBV in the HBV-WP
Residual risk estimation was based on the "HBsAg yield approach" [13] : The duration of HBsAg positivity until the onset of anti-HBc reactivity is the "yield window" of 44 days (0Á121 years) according to [13] ; the "test-negative window" is the time of HBV infectivity prior to HBsAg detection of 38 or 30 days (0Á104-0Á082 years), depending on an infection dose of 1 or 10 HBV DNA copies, as published [14] . The WP times for the HBV-NAT tests in this study were adjusted by adding (test-positive WP) or subtracting (test-negative WP) the time difference between HBsAg and HBV-NAT from the seroconversion study (Table S2 ). The yield is the number of HBsAg-or HBV-NAT-positive samples that were anti-HBc negative. The yield rate is the yield divided by the number of donations tested. The incidence rate is the yield divided by the test-positive WP. The residual risk is the incidence rate multiplied by the test-negative WP, presented as number of cases per 10 6 donations. Under the assumption of Poisson distribution, 95% confidence intervals (CI) for the yield rates were estimated according to an algorithm described by Daly [15] using SAS 9.4 (SAS Institute Inc., Cary, NC/USA). For incidence rate and residual risk, 95% CI were approximated by Monte Carlo simulation with Oracle Crystal Ball (Release 11.1.2.4.850), Oracle Corporation, Redwood City, CA/USA. For the test-positive WP, triangular distribution was assumed with the most likely value being 44Á0 days and the lower and upper 95% CI 27Á1 and 61Á2 days, respectively. For the test-negative WP, triangular distributions were assumed as well. For the 38Á3-day window, the lower and upper 95% CI were 33Á0 and 43Á7 days, and those for the 30Á0-day window were 25Á0 and 35Á0 days, respectively.
Results
HBsAg, anti-HBc and HBV-NAT screened donations in 2008-2015
Of the 51 participating BE, 45 270 111 donations were HBV-NAT tested (92Á8% of the donation volume in Germany) [1] , 600 000 by ID-NAT, otherwise by MP-NAT. There were 29 NAT-only cases (negative for HBsAg and anti-HBc), 28 identified by MP-NAT and one by ID-NAT ( Fig. 1 ). Detailed characterization of the 29 NAT-only cases is shown in Table S1 . The resulting yield rates were 0Á63 and 0Á64 per million donations for MP-NAT and total HBV-NAT-only, respectively.
Sensitivity performance of MP-NAT vs. HBsAg (seroconversion study)
Median viral load at positive HBsAg cut-off was 362 IU/ml (range 135-1502 IU/ml) ( Table 1 ). In comparison, the median MP-NAT-LoD in NAT-only was 146 IU/ml (range 58-675 IU/ml) over the entire investigation period, 208 IU/ml in the period 2008-2009 and 89 IU/ml in 2010-2015. MP-NAT was thus 3Á1 days earlier (LoD 146 IU/ml) in detection of HBV than the HBsAg tests (Table 2) , respectively, 2Á0 days (LoD 208 IU/ml) and 4Á8 days (LoD 89 IU/ml). Timing of HBV detection with all the various HBV-NAT and HBsAg tests used is shown in Fig. 2 . ID-NAT (LoD 1Á9 IU/ml) showed a significantly higher time gain in HBV detection of 17Á8 days compared to HBsAg and of 13-15Á8 days compared to MP-NAT. Furthermore, it should be noted that the HBV DNA concentration at the HBsAg cutoff varied considerably in the individual HBV seroconversion panels (range 135-1502 IU/ml; Table 1 ). As a result, also timing of HBsAg detection vs. HBV-NAT showed a wide range (Table 2) , for MP-NAT-LoD 146 IU/ml from -0Á3 to 10Á2 days. This correlated with different ratios of HBsAg subparticles to HBV virions ranging from 238 to 2631 with the median being 1002 (Table S2 ).
Viral loads in the NAT-only donations vs sensitivity of MP-NAT and HBsAg
The viral loads reported for 20 of the 29 NAT-only cases (Fig. 3) were compared with the positive HBsAg cut-off in the seroconversion study and the LoD of MP-NAT. Eight viral loads (<120 IU/ml) were below detection threshold of the HBsAg tests. Other eight viral loads were in the range (135-1502 IU/ml) in which HBsAg could only be positive with a certain probability. One HBsAg-negative sample at higher 1510 IU/ml HBV DNA tested in 2008 with a less sensitive HBsAg test, proved positive with the current HBsAg tests (Table 3) . One sample with a confirmed high viral load of 9Á2 9 10 3 IU/ml (Table 3) was HBsAg negative in eight tests, seronegative and HBeAg positive. Sequencing showed two escape mutations Q129R and F134L, as well as further mutations G44E L94S, M103T with unknown function and the dominant HBV genotype A2. Two other high viral loads (5 9 10 3 and 10 4 IU/ml) were estimated, with the corresponding uncertainty.
Residual risk of HBV in the anti-HBc-negative WP
Residual risk (Table 4 ) with MP-NAT-LoD of 146 IU/ml was 1:2 793 365 to 1:2 134 702, depending on an HBV infectious dose of 1 or 10 copies [14] . In comparison, the resid- HBsAg false-positive due to known HBV vaccination, or in retest, or no information Day difference relative to HBsAg c Minimum 
HBV-NAT 2008-2015 in chronic HBV, including occult HBV infection (OBI)
Breakdown of chronic HBV (HBsAg-/anti-HBc-positive) among the 45 270 111 HBV-NAT-tested donations is shown in Fig. 1 . A total of 482 donations were anti-HBc/ HBsAg positive and HBV-NAT negative. A total of 181 out of 257 (70%) were positive by supplemental testing with HBV-ID-NAT. Of these 181, 40 had a reported median viral load of 20 IU/ml (range 5-600 IU/ml). In addition, there were 261 HBsAg positive and anti-HBc negatives; 258 of them tested negative by ID-NAT. A total of 235 of these were HBsAg false positive due to previous HBV vaccination, 23 cases were unclear due to lack of information [16] . Among HBsAg positive/anti-HBc negatives was also one ID-NAT positive with HBsAg being only just above the cut-off (1Á1-1Á2) and ID-NAT below the limit of quantification (<10 IU/ml). Among the anti-HBc positive/HBsAg negatives ( Fig. 4 ), 23 OBI cases were identified by supplementary ID-NAT in repeat donors (42 101 203 [1] ), within 3649 anti-HBc "confirmed" positives. There were two other OBI reports for first-time donors.
Discussion
NAT-only cases from HBV-WP (2008-2015)
The survey revealed 29 HBV-NAT-only cases in donor screening, 28 with MP-NAT and one with ID-NAT, from the HBsAg-and anti-HBc-negative HBV-WP, corresponding to yield rates of 0Á63 and 0Á64 per million donations for MP-NAT-only and total HBV-NAT-only, respectively. This MP-NAT-only yield in the anti-HBc-negative HBV-WP is largely comparable to the previously published yield of 0Á70 per million donations in Germany (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) [7] and is in the range of more recent figures from the US of 0Á40 (2009-2011) [9] and 1Á30 per million donations (2011-2015) [10] . There was no confirmed HBsAg-only (HBV-NAT/anti-HBc negative) except one donation with extremely low viral load, which does not match the HBV-WP. This pattern is extremely rare [17] and not clearly classifiable [9, 10] .
Sensitivity performance of MP-NAT vs. HBsAg (seroconversion study)
The NAT-only yield was reflected in a higher sensitivity of MP-NAT compared to HBsAg tests. HBsAg detection required higher HBV DNA concentrations (median 362 IU/ml, 2100 copies/ml) than the median MP-NAT-LoD (146 IU/ml), resulting in a relatively significant delay of 3Á1 days in HBsAg detection due to the relatively long HBV doubling time (median 2Á44 days in this study). In addition, viral load at HBsAg cut-off showed a high variability ranging up to 1502 IU/ml, or a delay of 10Á2 days, significantly greater than the mean. There were also lower HBV DNA concentrations for positive HBsAg detection in single HBV seroconversion panels of up to 135 IU/ml with a small overlap between HBsAg and MP-NAT (-0Á3 days), which was still detected by NAT with a high probability of >90% based on probit analysis. This variability is due to different ratios of HBsAg particles to HBV virions between 238 and 2631. In addition, HBV DNA quantification may vary -0Á3 log 10 IU/ml depending on the test used, which is relevant for the low HBV DNA levels in HBV-WP. Therefore, an HBV DNA test was used in this study that was within the mean quantification level of several other tests [ [18] ; own data].
Viral loads in the NAT-only donations vs sensitivity of MP-NAT and HBsAg
The viral loads reported for the NAT-only donations confirmed a higher sensitivity of MP-NAT to HBsAg and correlated with the sensitivity range established in the seroconversion study (135-1502 IU/ml corresponding to 786-8740 copies/ml). One HBsAg-negative donation at a viral load of 9200 IU/ml that was expected to be HBsAg positive was due to HBsAg mutations that inhibited HBsAg detection and/or secretion. Interestingly, the identified HBsAg escape double mutation (Q129R and F134L) which has not been reported previously should be detectable as single mutations in the HBsAg tests used [19] . HBsAg negatives due to HBsAg mutations can still occur at higher viral loads (>10 3 -10 4 IU/ml), as already reported [20] . A relatively large proportion of eight out of 20 viral loads in the NAT-only cases was below the MP-NAT-LoD [6, 20] , partly considerably as with the two lowest viral loads (<11 IU/ml), corresponding to 10% of the effective LoD per ID in a MP of 96. 
Residual risk of HBV in the anti-HBc-negative WP
Evaluation of the timing of the various HBV tests (HBsAg, MP-and ID-NAT) allowed comparing the tests regarding their capacity to reduce the risk of HBV. The risk reduction by MP-NAT (LoD 146 IU/ml) compared to HBsAg averaged over 1-10 HBV copies was factor 1Á7 (1Á6-1Á9 for MP-NAT-LoD 208 and 89 IU/ml, respectively). Of note, the reported HBsAg-positive/anti-HBc-negative cases also were HBV-NAT positive, indicating that the residual risk of HBsAg was completely mitigated by HBV-NAT. ID-NAT (LoD 2 IU/ml) showed a risk reduction of factor 2Á2 compared to MP-NAT (LoD 146 IU/ml) and factor 3Á8 compared to HBsAg. This was modelled using the aggregated number of all potential 32 ID-NAT positives projected to the ID-NAT-specific-negative WP, as the actual number of ID-NAT-only cases (MP-NAT negative) is not known due to the comparatively low number of ID-NAT tested donations. It should be noted that, despite ID-NAT screening with the Procleix Ultrio Plus Assay, there was an HBV transmission case in 2012 with apheresis platelets 13 days prior to the ID-NAT positive donation (HBsAg/anti-HBc negative) at an approximated viral load of 3 IU/ml [2] , confirming a high infectivity of HBV below 10 copies (0Á35 copies/ml).
HBsAg and HBV-NAT performance during 2008-2015
HBV MP-NAT is the method commonly used in Germany adapted to the same pool size as for HIV-and HCV-NAT. [2] and do reflect the current status. Less sensitive HBsAg test versions were replaced in 2009 and 2011. The results of this study are, therefore, still valid for the current situation. It should be mentioned that currently more sensitive HBsAg tests are available with analytical sensitivity of 5Á0 mIU/ml [22, 23] , which can significantly reduce the gap to HBV-NAT to 73 IU/ml HBV DNA at the positive HBsAg cut-off (range 18-296 IU/ml) [data not shown].
HBV-NAT (2008-2015) in chronic HBV, including occult HBV infection (OBI)
Chronic HBV, including the late acute HBV phase, was the largest HBsAg-positive group with 482 HBsAg-/anti-HBc-positive cases (10Á6 per million donations). Supplementary ID-NAT could detect HBV DNA in 70% of these cases at low viral load (median 20 IU/ml), the other 30% remained ID-NAT negative, in line with other reports [9, 24] . HBsAg testing may, therefore, be necessary to determine the inactive HBsAg carrier status. 258 HBsAgreactive results in anti-HBc-and HBV-NAT-negative donations were false positive, due to a previous HBV vaccination. Twenty-three OBI cases were detected in repeat donors and two other OBI cases were reported from first-time donors. This resulted in an OBI incidence of 0Á55 per million donations. This is a similar OBI incidence as reported for the period 1997-2005 (0Á66 per million donations [7] ) in the same population prior to the introduction of anti-HBc screening. The OBI prevalence in the "confirmed" anti-HBc reactive cases was 0Á63% consistent with previously reported 0Á5-1Á0% for blood donations [7, 9] .
It is emphasized that anti-HBc screening introduced in 2006 has so far not missed HBV infections from chronic HBV, including OBI [2] .
Conclusion
In summary, HBV-NAT used during the period 2008-2015 detected significantly more HBV infections in the HBV-WP than HBsAg screening, 28 by MP-NAT and one by ID-NAT. MP-NAT, thus, reduced the residual risk of HBV transmission by a factor of 1Á7 compared to HBsAg screening. This was also reflected in a higher sensitivity of MP-NAT compared to HBsAg tests and was confirmed in the viral load of the NAT-only donations. With HBV-ID-NAT, the residual risk in HBV-WP can be further reduced by a factor of 2Á2 compared to MP-NAT. In later HBV stages, potentially infectious donations were intercepted by anti-HBc screening and HBV infectious donations were detected by supplementary ID-NAT.
